Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Not listed No phase listed Observational

PV Loop and Pulmonary Hypertension

NCT05484596
Conditions
Pulmonary Vascular Resistance Abnormality
Interventions
Measuring VA Coupling
Procedure
Lead sponsor
Hythem Nawaytou
Other
Eligibility
1 Year to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Actigraphy in Pediatric Pulmonary Hypertension

NCT02909608
Conditions
Pediatric Pulmonary Hypertension
Interventions
No interventions / observations only
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 14 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Aurora, Colorado
Conditions
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation, Pediatric Cardiology, Telehealth, Telerehabilitation
Interventions
Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Pulmonary Hypertension
Interventions
Ultrasound Doppler
Radiation
Lead sponsor
Echosense Ltd.
Industry
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Palo Alto, California
Conditions
Pulmonary Arterial Hypertension
Interventions
mHealth Intervention, Usual Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 3 Interventional Results available

FUTURE 3 Study Extension

NCT01338415
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Months to 12 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
Conditions
Pulmonary Hypertension
Interventions
Exercise intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypertension, Pulmonary
Interventions
Assigned pulmonary hypertension medication
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Conditions
Pulmonary Arterial Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Denver, Colorado • New York, New York
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil- Tablet or Oral suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Association for Pediatric Pulmonary Hypertension
Other
Eligibility
3 Months to 18 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 10 more
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions
Blood pressure, Urine protein
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
20,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Hypertension
Interventions
Obtain blood specimens
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
PAH
Interventions
oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension

NCT04745000
Conditions
Hypertension;Pulmonary;Primary
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 6 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pulmonary Hypertension, Congenital Heart Disease, Pediatric Congenital Heart Disease
Interventions
cardiac catheterization, Cardiac MRI
Procedure · Radiation
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 25 Years
Enrollment
35 participants
Timeline
2017 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Ambrisentan in Children 8-18yrs

NCT01332331
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan - low dose, Ambrisentan - high dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio